{"id":"zn-c3","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT05743036"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2024","type":"negative","milestone":"Phase 1 Initiated","description":"Phase 1 trial (ZN-c3 in Adult Participants With Metastatic Colorectal Cancer) — Metastatic Colorectal Cancer. Trial terminated early."}],"aiSummary":"Unable to provide summary: ZN-c3 lacks FDA mechanism text and approved indication data in the provided information. Please verify drug name and provide complete FDA prescribing information for accurate clinical summary.","brandName":"ZN-c3","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"ZN-c3 tablet by mouth, in combination with encorafenib","explanation":"","oneSentence":"ZN-c3 tablet by mouth, in combination with encorafenib","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"zn-c3","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Metastatic Colorectal Cancer","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05743036","phase":"Phase 1","title":"ZN-c3 in Adult Participants With Metastatic Colorectal Cancer","status":"Terminated","sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","isPivotal":false,"enrollment":44,"indication":"Metastatic Colorectal Cancer","completionDate":"2024-07","primaryEndpoint":"The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metast"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL5095036","pubchemSID":"443566415"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":4,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}